EC Number   |
Inhibitors  |
Structure |
|---|
   2.3.1.B41 | methyl N2-acetyl-N6-ethanethioyl-L-lysyl-L-alaninate |
0.2 mM, 20% inhibition, substrate: Ac-RYQ(N6-acetyl)K-7-amido-4-methylcoumarin |
   |
| 2.3.1.B41 | more |
splitomicin and sirtinol fail to inhibit PfSir2 |
|
| 2.3.1.B41 | more |
nicotinamide insensitivity, IC50: 2.1 mM |
|
| 2.3.1.B41 | more |
not inhibited by linoleic acid, oleic acid, oleoylethanolamide, and myristoylethanolamide |
|
| 2.3.1.B41 | more |
preparation of the 4-substituited-4,5-dihydropyrrolo[1,2-a]quinoxalines and 4-substituited-pyrrolo[1,2-a]quinoxalines |
|
| 2.3.1.B41 | more |
identification of SIRT6 inhibitors that decrease SIRT6 deacetylase activity and evoke coherent biological effects in cells. These inhibitors include a family of compounds with a quinazolinedione-based structure and a family of compounds with salicylate-based structure, with an IC50 for the SIRT6-catalyzed deacetylase activity in the low micromolar range. Relative enzyme activity in presencee of inhibitors compared to control, overview. No inhibition by (9H-fluoren-9-yl)methyl [(2S)-6-[(tert-butoxycarbonyl)amino]-1-(dodecylamino)-1-oxohexan-2-yl]carbamate and tert-butyl [(5S)-5-acetamido-6-(dodecylamino)-6-oxohexyl]carbamate |
|
| 2.3.1.B41 | N,N'-(6-(octadecylamino)-6-oxohexane-1,5-diyl)diacetamide |
- |
|
| 2.3.1.B41 | N-[(5S)-5-acetamido-6-(dodecylamino)-6-oxohexyl]-N,N-dimethylmethanaminium |
- |
|
| 2.3.1.B41 | N2-acetyl-N-dodecyl-L-lysinamide |
- |
|
| 2.3.1.B41 | N2-[(benzyloxy)carbonyl]-N6-ethanethioyl-N-(2-fluorophenyl)-L-lysinamide |
0.2 mM, 25% inhibition, substrate: Ac-RYQ(N6-acetyl)K-7-amido-4-methylcoumarin |
|
